etavopivat
etavopivat: developed by 1 company · 12 clinical trials tracked.
etavopivat evidence translation
What we can confirm
12 tracked trials
What it means
What to watch
Prepared research question
How could etavopivat → FMTX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Forma Therapeutics Holdings, Inc. (FMTX) Sickle Cell Disease; Very Low Risk, Low Risk, or Intermediat… | Phase 2 |
Clinical Trials (12)showing 10 most recent
A Study to Assess the Effect of Etavopivat on Cardiac Repolarisation in Healthy Participants
Primary endpoint: Part A: Number of treatment-emergent adverse events (AEs)
A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease
Primary endpoint: Number of adjudicated Vaso-occlusive crisis (VOC) events with a medical contact
An Open-Label, Fixed-Sequence Study to Evaluate the Effect of Etavopivat on the Single-Dose Pharmacokinetics of Midazolam, Digoxin, Rosuvastatin, Pitavastatin, and Metformin in Healthy Adult Participants
Primary endpoint: Cmax, digoxin, SD: Maximum observed digoxin plasma concentration with and without etavopivat at steady state
A Single-centre, Open-label, Single-group Study Investigating the Pharmacokinetics, Safety and Tolerability After a Single Dose of Oral Etavopivat in Healthy Chinese Participants
Primary endpoint: AUC0-inf,etavopivat: Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose
A Single-centre, Open-label, Randomised, Single-dose, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of Etavopivat in Healthy Participants
Primary endpoint: AUC0-inf, etavopivat: Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose
A Multi-centre, Open-label, Parallel-group Study Investigating the Pharmacokinetics, Safety and Tolerability After a Single Dose of Oral Etavopivat in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Participants With Normal Hepatic Function
Primary endpoint: Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose (AUC0-inf, etavopivat)
A Pilot Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
Primary endpoint: Effect of etavopivat on cerebral blood flow (CBF)
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
Primary endpoint: Change in the highest TAMMV in any of the L/R internal carotid artery [ICA] and L/R middle cerebral artery [MCA], whichever is highest, as measured by TCD
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Primary endpoint: Single-dose: maximum plasma concentration (Cmax)
A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
Primary endpoint: Percentage of Participants With Hematologic Improvement- Erythroid (HI-E) Response for >=8 Weeks Within 24 Weeks of Etavopivat Treatment
Frequently asked questions
Who is developing etavopivat?
etavopivat is being developed by Forma Therapeutics Holdings, Inc..
How many clinical trials involve etavopivat?
BioSniper tracks 12 clinical trials involving etavopivat.